Erleada for Non-metastatic castration-resistant prostate cancer
Quick answer: Erleada is used for Non-metastatic castration-resistant prostate cancer as part of a androgen receptor inhibitor (next-generation antiandrogen) treatment regimen. Selective androgen receptor inhibitor that blocks androgen binding, nuclear translocation, and DNA binding The specific dosing for Non-metastatic castration-resistant prostate cancer is determined by your prescriber based on individual factors.
Why is Erleada used for Non-metastatic castration-resistant prostate cancer?
Erleada belongs to the Androgen receptor inhibitor (next-generation antiandrogen) class. Selective androgen receptor inhibitor that blocks androgen binding, nuclear translocation, and DNA binding This action makes it useful for treating or managing Non-metastatic castration-resistant prostate cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Erleada is the right choice for a specific patient depends on the type and severity of Non-metastatic castration-resistant prostate cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Non-metastatic castration-resistant prostate cancer
Common adult dosing range: 240 mg orally once daily. The actual dose for Non-metastatic castration-resistant prostate cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Erleada medicine page.
What to expect
Erleada treatment for Non-metastatic castration-resistant prostate cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Non-metastatic castration-resistant prostate cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Erleada is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Androgen receptor inhibitor (next-generation antiandrogen) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Erleada
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Erleada full prescribing information · All Androgen receptor inhibitor (next-generation antiandrogen) alternatives
Frequently asked questions
How effective is Erleada for Non-metastatic castration-resistant prostate cancer?
Effectiveness varies by individual response, dose, and severity. Erleada is one of several treatment options for Non-metastatic castration-resistant prostate cancer, supported by clinical evidence within the androgen receptor inhibitor (next-generation antiandrogen) class. Discuss expected response with your prescriber.
How long do I need to take Erleada for Non-metastatic castration-resistant prostate cancer?
Treatment duration depends on the nature of Non-metastatic castration-resistant prostate cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Erleada when used for Non-metastatic castration-resistant prostate cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Erleada for Non-metastatic castration-resistant prostate cancer?
Yes. Multiple medicines and non-drug options exist for Non-metastatic castration-resistant prostate cancer. Alternatives within the androgen receptor inhibitor (next-generation antiandrogen) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.